ATC Group: A10BD09 Pioglitazone and alogliptin

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A10BD09 in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A10 Drugs used in diabetes
3 A10B Blood glucose lowering drugs, excl. insulins
4 A10BD Combinations of oral blood glucose lowering drugs
5 A10BD09 Pioglitazone and alogliptin

Active ingredients in A10BD09

Active Ingredient Description
Pioglitazone and Alogliptin

Combination of two antihyperglycaemic medicinal products with complementary and distinct mechanisms of action to improve glycaemic control in patients with type 2 diabetes mellitus: alogliptin, a dipeptidyl-peptidase-4 (DPP-4) inhibitor, and pioglitazone, a member of the thiazolidinedione class.

Related product monographs

Title Information Source Document Type  
INCRESYNC Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Austria (AT)

Brazil (BR)

Croatia (HR)

Estonia (EE)

Finland (FI)

Hong Kong (HK)

Ireland (IE)

Italy (IT)

Lithuania (LT)

Mexico (MX)

Poland (PL)

Spain (ES)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.